Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Acute Myeloid Leukemia (AML) patient xenografts

ABSTRACT: Acute Myeloid Leukemia (AML) patient xenografts

PROVIDER: PRJNA736604 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14777110.fastq.gz	Fastqsanger.gz
	SRR14777111.fastq.gz	Fastqsanger.gz
	SRR14777112.fastq.gz	Fastqsanger.gz
	SRR14777113.fastq.gz	Fastqsanger.gz
	SRR14777114.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 62

Similar Datasets

Imetelstat is effective in Acute Myeloid Leukemia (AML) patient xenografts.

Project description:Imetelstat is effective in Acute Myeloid Leukemia (AML) patient xenografts.

| PRJNA736609 | ENA

Imetelstat is effective in Acute Myeloid Leukemia (AML) patient xenografts.

Project description:Imetelstat is a covalently lipidated 13-mer thiophosphoramidate oligonucleotide that competitively inhibits telomerase activity. Here, we show that imetelstat effectively diminishes AML burden and prolongs survival in a comprehensive, randomized Phase II-like preclinical trial in AML patient-derived xenografts (PDX).

2023-07-14 | GSE176523 | GEO

The phosphoproteomic landscape of two FLT3+ Acute Myeloid Leukemia (AML) patient samples.

Project description:Acute myeloid leukemia (AML) is a clonal hematopoietic malignancy, characterized by expansion of immature leukemic blasts in the bone marrow. In AML, specific tyrosine kinases have been implicated in leukemogenesis, and are associated with poor treatment outcome. However, targeted therapy using kinase inhibitors (KIs) has had limited success, and may be improved by proper patient selection. We performed phosphotyrosine (pY) based, label-free phosphoproteomics to identify hyperphosphorylated, active kinases in two FLT3+ AML Pt samples.

2020-03-02 | PXD015639 | Pride

Proteomic profiling of AML patient-derived xenografts across serial transplantation

Project description:This dataset contains mass spectrometry-based proteomic profiling of acute myeloid leukemia patient-derived xenograft samples collected across serial transplantation stages. The study aimed to characterize proteome remodeling associated with leukemia propagation and disease evolution in AML PDX models. Proteomic data were generated from xenografted human AML cells and are part of a broader multi-omics study integrating serial xenotransplantation, transcriptomics, proteomics and functional therapeutic analyses.

2026-07-20 | PXD078079 | Pride

The phosphoproteomic landscape of two FLT3+ Acute Myeloid Leukemia (AML) patient samples-LYSATES.

2020-03-02 | PXD015662 | Pride

OGFOD1 enables AML chemo- and nutrient stress resistance by regulating protein synthesis

Project description:<p>Acute Myeloid Leukemia (AML) commonly relapses after initial chemotherapy response. We assessed metabolic adaptations in chemoresistant cells in vivo before overt relapse, identifying altered branched-chain amino acid (BCAA) levels in patient-derived xenografts (PDX) and immunophenotypically identified leukemia stem cells from AML patients. Notably, this was associated with increased BCAA transporter expression with low BCAA catabolism. Restricting of BCAAs further reduced chemoresistant AML cells but relapse still occurred. Among the persisting cells we found an unexpected increase in protein production. This was accompanied by elevated translation of 2-oxoglutarate-and-iron-dependent oxygenase 1 (OGFOD1), a known ribosomal dioxygenase that adjusts the fidelity of tRNA anticodon pairing with coding mRNA1–3 and upregulates protein synthesis in AML driving disease aggressiveness. Inhibiting OGFOD1 impaired translation processing, decreased protein synthesis and improved animal survival even with chemoresistant AML through regulation of protein synthesis. Leukemic cells can therefore persist despite the stress of chemotherapy and nutrient deprivation through adaptive control of translation while sparing normal hematopoiesis. Targeting OGFOD1 may offer a distinctive, translation modifying means of reducing the chemopersisting cells that drive relapse.</p>

2025-07-19 | MTBLS10255 | MetaboLights

Translational remodeling across serial xenotransplantation in acute myeloid leukemia patient-derived xenografts

Project description:Translational remodeling across serial xenotransplantation in acute myeloid leukemia patient-derived xenografts

| PRJNA1462680 | ENA

Gene expression data from sorted and unsorted primary human acute myeloid leukemia (AML) samples

Project description:Experiments using xenografts show that some solid tumours and leukemias are organized as cellular hierarchies sustained by cancer stem cells (CSC). Despite promise, the relevance of the CSC model to human disease remains uncertain. Here we show that acute myeloid leukemia (AML) follows a CSC model based on sorting multiple populations from each of 16 primary human AML samples and identifying which contain leukemia stem cells (LSC) using a sensitive xenograft assay. Analysis of gene expression from all functionally validated populations yielded an LSC-specific signature. Similarly, a hematopoietic stem cell (HSC) gene signature was established. Bioinformatic analysis identified a core transcriptional program shared by LSC and HSC, revealing the molecular machinery underlying stemness properties. Both stem cell programs were highly significant independent predictors of patient survival and also found in existing prognostic signatures. Thus, determinants of stemness influence clinical outcome of AML establishing that LSC are clinically relevant and not mere artifacts of xenotransplantation. Analysis of gene expression in FACS sorted AML fractions that were functionally determined to be enriched for LSC or not (25 and 29 respectively).

2011-08-27 | E-GEOD-30375 | biostudies-arrayexpress

DNA methylation remodeling across serial xenotransplantation in acute myeloid leukemia patient-derived xenografts

Project description:DNA methylation remodeling across serial xenotransplantation in acute myeloid leukemia patient-derived xenografts

| PRJNA1462679 | ENA

Generation of a unique, comprehensive and representative Acute Myeloid Leukemia (AML) patient-derived xenograft (PDX) resource.

Project description:Randomized Phase II-like preclinical trials in patient-derived xenografts (PDX) provide an attractive option to define the efficacy of drugs that act via cell-intrinsic mechanisms, and to identify biomarkers of response and resistance across genetically diverse subtypes of leukemia. Here, we generated a unique, comprehensive and representative AML PDX resource that reflects the genetic abnormalities that are found in large clinical trials.

2023-07-14 | GSE176522 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data